Showing 941-950 of 1043 results for "".
- FDA Accepts Investigator Sponsored IND of ENT-01 to Treat a Patient with Prodromal Multisystem Atrophyhttps://practicalneurology.com/news/fda-accepts-investigator-sponsored-ind-of-ent-01-to-treat-a-patient-with-prodromal-multisystem-atrophy/2470206/The Food and Drug Administration (FDA) has accepted an investigator sponsored Investigational New Drug (IND) application (166532) for the use of ENT-01 (squalamine phosphate, Enterin Inc, Philadelphia, PA) to treat a patien
- Recall Issued for Phillips DreamStation CPAP, BIPAP Machineshttps://practicalneurology.com/news/recall-issued-for-phillips-dreamstation-cpap-bipap-machines/2470152/The Food and Drug Administration (FDA) issued a recall for certain models of DreamStation1 devices (Phillips Respironics, Murrysville, PA) distributed in the United States from December 1, 2021 through October 31, 2022
- Phase 3 Trial for Buntanetap for Parkinson Disease Initiatedhttps://practicalneurology.com/news/phase-3-trial-for-buntanetap-for-parkinson-disease-initiated/2469966/A phase 3 trial (NCT05357989) of buntanetap (Annovis Bio, Berwyn, PA) for Parkinson disease (PD) has been okayed by the Food and Drug Administration (FDA). People with early PD (Hoehn & Yahr [
- Lower-Sodium Oxybate Maintains Narcolepsy Symptom Relief, Reduces Dizziness and Sweating, and Is Preferred by Patientshttps://practicalneurology.com/news/lower-sodium-oxybate-maintains-narcolepsy-symptom-relief-reduces-dizziness-and-sweating-and-is-preferred-by-patients/2469926/Interim data analysis from the TENOR trial (NCT04803786) shows people with narcolepsy who switched from sodium oxybate (Xyrem; Jazz Pharmaceuticals, Philadelphia, PA) to lower-sodium oxybate (Xywav; Jazz Pharmaceuticals) maintained sym
- Long-Term Efficacy and Safety of Low Sodium Oxybate for Idiopathic Hypersomniahttps://practicalneurology.com/news/long-term-efficacy-and-safety-of-low-sodium-oxybate-for-idiopathic-hypersomnia/2469876/In the double-blind clinical trial (NCT03533114) of lower sodium oxybate (Xywav; Jazz Pharmaceuticals, Philadelphia, PA), individuals with idiopathic hypersomnia (IH) who continued using a titrate
- Posiphen Treatment Provides Clinical Improvement of Alzheimer and Parkinson Disease in Clinical Trialshttps://practicalneurology.com/news/posiphen-treatment-provides-clinical-improvement-of-alzheimer-and-parkinson-disease-in-clinical-trials/2469787/In phase 1 and 2 studies (NCT04524351), respectively, people with early Alzheimer disease (AD) and early Parkinson disease (PD) who were treated with posiphen (ANVS401; Annovis, Berwyn, PA) had statistically significant clinical improv
- Suvecaltimide for Essential Tremors Clinical Trial Enrolls First Participanthttps://practicalneurology.com/news/suvecaltimide-for-essential-tremors-clinical-trial-enrolls-first-participant/2469781/The first participant has been enrolled in the phase 2b clinical trial (NCT05122650) of suvecaltamide (JZP385; Jazz Pharmaceuticals, Philadelphia, PA) as potential treatment of moderate-to-se
- Pitolisant Post Hoc Analysis Shows Rapid Onset of Response for Narcolepsy Symptomshttps://practicalneurology.com/news/pitolisant-post-hoc-analysis-shows-rapid-onset-of-response-for-narcolepsy-symptoms/2469778/As published in CNS Drugs, post hoc analysis of clinical trial data shows a 2- to 3-week time to onset of response to pitolisant (Wakix; Harmony Biosciences, Plymouth Meeting, PA). Onset of response, mea
- Ganaxolone Reduces Seizure Frequency in Tuberous Sclerosis Complexhttps://practicalneurology.com/news/ganaxolone-reduces-seizure-frequency-in-tuberous-sclerosis-complex/2469673/In an open-label phase 2 trial (NCT04285346), ganaxolone (Marinus Pharmaceuticals, Radnor, PA) treatment of 23 participants with seizures associated with tuberous sclerosis complex (TSC) reduced s
- Pitolisant Clinical Trial for Type 1 Myotonic Dystrophy Excessive Daytime Sleepinesshttps://practicalneurology.com/news/pitolisant-clinical-trial-for-type-1-myotonic-dystrophy-excessive-daytime-sleepiness/2469633/A phase 2 clinical trial (NCT04886518) for pitolisant (Wakix; Harmony Biosciences, Plymouth Meeting, PA) in adults with type 1 myotonic dystrophy (DM1) experiencing excessive daytime sleepiness (E